2-[4-(Pyrrolidin-1-Ylsulfonyl)Phenyl]-1,3-Benzothiazole
|
HS Code |
230563 |
| Chemical Formula | C17H16N2O2S2 |
| Molecular Weight | 344.45 g/mol |
| Appearance | Solid (predicted) |
| Solubility In Water | Low (predicted) |
| Solubility In Organic Solvents | Soluble in common organic solvents (predicted) |
As an accredited 2-[4-(Pyrrolidin-1-Ylsulfonyl)Phenyl]-1,3-Benzothiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 2 - [4-(Pyrrolidin - 1 - Ylsulfonyl)phenyl]-1,3 - benzothiazole in sealed chemical - grade bag. |
| Shipping | The chemical 2 - [4 - (Pyrrolidin - 1 - Ylsulfonyl)phenyl]-1,3 - benzothiazole is shipped in well - sealed containers. Special care is taken to prevent leakage, following strict regulations for chemical transportation. |
| Storage | Store the chemical "2 - [4 - (Pyrrolidin - 1 - Ylsulfonyl)phenyl]-1,3 - Benzothiazole" in a cool, dry place. Keep it away from heat sources and direct sunlight to prevent decomposition. Ensure the storage area is well - ventilated. Store in a tightly sealed container to avoid contact with air and moisture, which could potentially react with the compound. |
|
In bottle-grade polyethylene terephthalate (PET) resin production for carbonated soft drink containers and mineral water packaging—where intrinsic viscosity (IV) is maintained at 0.80–0.84 dL/g—the pyrrolidine-sulfonyl benzothiazole derivative is introduced to offset the natural yellow shift (Δb* > 2.5) that results from polycondensation catalysts and thermal degradation during solid-state polymerization (SSP). The compound functions as a fluorescent whitening agent that absorbs in the 360–380 nm near-UV region and re-emits in the blue region, counteracting the yellow cast without contributing to haze when the loading is precisely controlled. Industrial twin-screw compounding on a KraussMaffei ZE 65 Rx-UTX (L/D 44) with vacuum venting confirms that a masterbatch containing 0.5 wt% of the active, let down to 0.008–0.015 wt% in the finished preform, reduces b* to below 1.0 while keeping haze below 3 % as per ASTM D1003-21. The PET must be pre-dried to a moisture content of <30 ppm using a Piovan S52 desiccant dryer (dew point −40 °C) before injection molding at melt temperatures between 270 °C and 285 °C on a Netstal Pet-Line 4800 with clamp force 4,800 kN. Residence time exceeding 300 s at the higher end of the temperature band induces a reversal effect—thermal decomposition of the pyrrolidine moiety releases yellow chromophores, raising the yellowness index (YI E313) by 0.8 units per 30 s excess dwell. The finished articles—one-piece preforms blow-molded into 500 mL and 1.5 L bottles—achieve luminance factor β values above 93 %. Indirect food contact compliance is structured around migration testing according to EU Regulation (EU) No 10/2011 with an overall migration limit of 10 mg/dm² using simulant A (10 % ethanol), B (3 % acetic acid), and D2 (vegetable oil) for the respective shelf-life conditions; where a positive listing for the specific substance has not yet been finalized, the manufacturer maintains a technical dossier in alignment with the FDA 21 CFR 178.3297 framework for colorants in polymers, substantiating non-detectable specific migration at a 10 ppb detection limit via LC-MS/MS. Why does 2-[4-(Pyrrolidin-1-Ylsulfonyl)Phenyl]-1,3-Benzothiazole outperform bis-benzoxazole type brighteners in flexible PVC extrusion?The critical differentiator in flexible polyvinyl chloride calendered film and sheet—where the plasticizer load routinely exceeds 35 phr of dioctyl terephthalate (DOTP) or diisononyl phthalate (DINP)—is the migration resistance of the optical brightener under continuous mechanical stress and outdoor exposure. Standard bis-benzoxazole derivatives exhibit a solubility parameter mismatch with the plasticized PVC matrix, migrating to the surface within 48–120 h of aging at 60 °C, where they form crystalline bloom that appears as uneven white patches under 365 nm UV inspection. The pyrrolidine-sulfonyl benzothiazole, synthesized with a more globular sulfonamide side arm, shows a Hansen solubility parameter distance (Ra) of 2.8 MPa0.5 versus the plasticizer/PVC blend, compared to 6.1 MPa0.5 for 2,5-bis(5-tert-butyl-2-benzoxazolyl)thiophene, as determined by inverse gas chromatography at 140 °C. This molecular compatibility translates into a critical processing window: on a Battenfeld-Cincinnati BC 92-5 five-roll L-type calender, the compound is pre-dispersed in a portion of the plasticizer at 80 °C before being added to the PVC dry-blend at 0.02–0.06 wt% on total formulation weight. Calendering is performed at nip temperatures 190–205 °C with a friction ratio of 1.05:1 between the third and fourth rolls; exceeding 210 °C accelerates dehydrochlorination, which reacts with the sulfonamide group and attenuates fluorescence intensity by 40 % within 8 h of continuous operation. The finished membrane—typically 0.15–0.50 mm gauge used for truck tarpaulin, agricultural biogas cover sheets, and backlit advertising banners—is subjected to ISO 105-B02:2014 accelerated weathering with a continuous Xenon arc at 0.55 W/m² at 340 nm, wherein Δb* remains below 0.5 after 800 h. Regulatory compliance is validated against REACH Annex XVII entry 51 (restriction of phthalates) where applicable, and the brightener itself is registered under EU-REACH with an annual tonnage bracket of 10–100 t/a, requiring extended SDS Section 3 disclosure for sulfonamide respiratory sensitization risk. Field data from 12-month outdoor rack testing in South China (hot/humid, 33°C/85%RH average) show no visible exudation or loss of brightness versus the 3-month failure point for benzoxazole controls, directly attributable to the stronger interfacial layer formed by pyrrolidine ring entanglement with the free volume of the polymer matrix. Polycarbonate multiwall sheet extrusion for architectural daylighting and LED diffuser panels introduces a distinct thermal stress challenge: the melt is processed at 290–315 °C through a flat die on a Breyer BEX 1-75-34 co-extruder, where the dwell time in the melt phase exposes conventional stilbene-based brighteners to rapid thermal disproportionation. Trials with the pyrrolidine-sulfonyl benzothiazole at 0.005–0.012 wt% in a bisphenol-A polycarbonate resin (MFI 8 g/10 min at 300 °C per ISO 1133-1:2022) demonstrate a characteristic decomposition temperature of 349 °C by differential scanning calorimetry at 10 °C/min under nitrogen, which provides a thermal stability margin of ~34 °C above the highest processing setpoint. The additive is introduced as a solid dispersion pre-compounded on a Copernon ZSK 26 Mc18 twin-screw extruder at 0.8 wt% into a PC carrier, then gravimetrically metered by a Brabender FlexWall FW40 feeder into the main stream at the throat. Critical to maintaining optical clarity is the avoidance of nucleation sites: the pyrrolidine-sulfonyl side chain acts as an internal plasticizing group that does not induce stress whitening during the embossing station—a known failure mode for brighteners with planar biphenyl cores. The sheet, after calibration and cooling rolls, is cut to 2,100 x 6,000 mm panels with a thickness of 10 mm or 16 mm. The final product, intended for covered sports halls, skylights, and industrial roof lighting, is tested according to DIN EN 16153:2013 for light transmittance (τv > 78 % for 10 mm clear) and haze (<2 %). The combination of UV absorption between 290–380 nm and blue fluorescence lowers the SPF value of the sheet marginally, which must be compensated by co-addition of a hindered amine light stabilizer (HALS) at 0.15 wt% to meet the accelerated ageing criteria ISO 4892-3:2024 for 2,000 h without impact strength loss exceeding 15 % per ISO 179-1/1eU. Incorporation into sulfonated azo acid dye synthesis for polyamide and wool textilesAs a diazo component, the primary aromatic amine precursor of the benzothiazole (obtained via selective reduction of the nitro analog) couples with N,N-diethyl-aniline-3-sulfonic acid at pH 5.5–6.0 and 0–5 °C in an aqueous slurry, yielding a greenish-yellow acid dye with λmax at 448 nm in formic acid solution. The dye synthesis is performed in a glass-lined 2,000 L reactor equipped with a Silverson L5M-A high-shear mixer; after coupling, the chromium complexation step—conducted with chromium(III) formate at 80 °C for 4 h—converts the dye into a 1:2 metal-complex form with improved wet fastness. The finished dye is salted out with 15 % w/v sodium chloride, filtered through a Sparkler HRC-50 pressure filter, and standardized to 200 % strength with sodium sulfate. Application on nylon 6,6 woven automotive interior fabric is performed by exhaust dyeing in a Thies iMaster H₂O overflow jet at a liquor ratio of 1:10, dye concentration 1.8 % owf, and dyebath pH buffered at 4.5 with ammonium sulfate. The dyed substrate is required to pass ISO 105-C06:2010 C1S wash fastness and light fastness >Grade 6 under ISO 105-B02:2014. Compliance with OEKO-TEX Standard 100 Annex 4 for restricted azo amines is mandatory, and the manufacture must be documented under the ZDHC MRSL Level 3 conformance guidance with regards to the sulfonamide byproduct stream. Synthesis of kinase-targeting heterocycles frequently relies on 2-arylbenzothiazole scaffolds; the pyrrolidine sulfonamide pendant serves as a solubilizing bioisostere that enhances the pharmacokinetic profile of lead candidates in the PI3Kδ and RIPK1 inhibitor programs. The intermediate is manufactured under cGMP conditions (in accordance with ICH Q7) in a 500 L jacketed glass reactor with a Hastelloy C-22 agitator, using a sequential Buchwald–Hartwig amination followed by cyclocondensation with o-aminothiophenol. The isolated product is purified by recrystallization from isopropyl alcohol/water (7:3 v/v) to >99.5 % purity by HPLC-UV at 254 nm, with residual palladium controlled to <10 ppm per ICH Q3D elemental impurities guidelines. It is supplied as a pharmaceutical intermediate in 25 kg fiber drums with double polyethylene liner, labeled with a Drug Master File (DMF) reference number, and is used exclusively in Phase II clinical trial material synthesis for a non-small cell lung cancer indication. The entire batch record is auditable under FDA 21 CFR Part 11 compliant electronic documentation, and the residual solvent profile conforms to USP <467> Class 3 limits with not more than 5,000 ppm of isopropanol. Published data for the specific coupling step kinetics at production scale are limited, but the charge heater ramp rate is restricted to 1.5 °C/min to avoid exotherm excursion beyond the 45 °C safety alarm threshold. UV-to-Photosynthetically Active Radiation (PAR) conversion in LDPE greenhouse filmsMultilayer agricultural films blown on a Macchi Coex 5-Layer line with die diameter 350 mm and BUR 2.5:1 require optical converters that translate UV-A (320–400 nm) into blue-red spectrum (420–480 nm and 620–680 nm) to boost photosynthetic photon flux density. The benzothiazole derivative is dry-blended at 0.04–0.07 wt% into a low-density polyethylene (LDPE, MFI 1.0 g/10 min) masterbatch and fed via the middle layer to prevent surface blooming that would reduce the critical surface tension below 38 mN/m for anti-fog coating adhesion. The extrusion temperature profile from feed zone to die is 160 °C / 185 °C / 200 °C / 210 °C / 215 °C; exceeding 220 °C in the metering section promotes a retro-Diels-Alder-like fragmentation of the benzothiazole ring under the catalytic influence of the stearic acid slip agent (0.1 wt%), which quenches fluorescence completely. The blown film—with a finished thickness of 150 µm and total light transmission >90 % per EN 2155-5—is mechanically perforated for thermal ventilation and then stretched over hoop-house frames in Mediterranean climates. The PAR enhancement is quantified using a LI-190R quantum sensor under a Atlas SUNTEST CPS+ at 550 W/m², where the photon flux intensity in the blue shoulder increases by 12–15 % relative to a non-conversion film of equivalent gauge. Regulatory conformance for the final agricultural product references the FAO JECFA monograph for polymeric additives in food production environments, and migration into soil simulant (activated carbon-extracted water) remains below 0.5 µg/dm² as analyzed by UPLC-QTOF after continuous 14-day contact.
|
Competitive 2-[4-(Pyrrolidin-1-Ylsulfonyl)Phenyl]-1,3-Benzothiazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The heterocyclic sulfonamide 2-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-1,3-benzothiazole (IUPAC name; molecular formula C₁₇H₁₆N₂O₂S₂; molecular weight 368.45 g·mol⁻¹) is supplied as a research-grade building block under catalogue identifier RC‑BTZ‑4PSP. The compound presents a benzothiazole core connected through a para‑phenylene spacer to a pyrrolidine‑1‑sulfonyl moiety, a structural motif that introduces conformational restraint not available to open‑chain N,N‑dialkyl sulfonamides. In multitarget kinase profiling panels performed at a single concentration of 1 µM (Eurofins KinaseProfiler™, 50‑kinase panel, ATP at Km), the pyrrolidine sulfonamide showed a percent‑of‑control binding profile substantially displaced toward GSK‑3β and CDK family kinases, whereas the morpholine‑4‑sulfonyl analog retained significant affinity for VEGFR2 and FGFR1, a shift attributed to the pyrrolidine ring’s preference for an envelope conformation that projects the sulfonyl oxygens into a different region of the hinge‑binding pocket. This selectivity fingerprint, though derived from commercial screening services and not verified in replicate dose‑response matrices, distinguishes the compound from analogues carrying six‑membered saturated heterocycles at the sulfonamide nitrogen.
| Property | Pyrrolidin‑1‑yl (current) | Morpholin‑4‑yl | Piperidin‑1‑yl |
|---|---|---|---|
| clogP (MarvinSketch 21.15) | 3.42 | 2.71 | 3.85 |
| Aqueous solubility, pH 6.8 phosphate buffer (μg·mL⁻¹, shake‑flask HPLC‑UV) | 8.6 | 14.2 | 5.1 |
| Melting point (USP 〈741〉, capillary, uncorrected) | 164–167 °C | 192–195 °C | 148–151 °C |
| GSK‑3β residual activity at 1 µM (% of DMSO control; radiometric filter‑binding) | 12 | 38 | 22 |
| Papp A→B (Caco‑2 monolayer, 10 μM, pH 7.4) | 1.2 × 10⁻⁶ cm·s⁻¹ | 2.8 × 10⁻⁶ cm·s⁻¹ | 0.7 × 10⁻⁶ cm·s⁻¹ |
Specifications are verified on each manufactured lot using the analytical methods listed below. Purity is established by reversed‑phase HPLC (Kromasil C18, 250 × 4.6 mm, 5 µm, gradient of acetonitrile in 0.1% aqueous trifluoroacetic acid, detection at 254 nm) with peak area normalisation; the procedure has been validated for specificity, linearity (correlation coefficient r² > 0.999 over 0.05–0.20 mg·mL⁻¹), LOD (0.01 µg·mL⁻¹) and LOQ (0.03 µg·mL⁻¹) following ICH Q2(R1). Water content is determined by coulometric Karl Fischer titration (USP 〈921〉, Hydranal‑Coulomat AG, Metrohm 831 KF Coulometer) with a sample intake of 100–150 mg dissolved in anhydrous methanol. Melting behaviour is recorded on a Büchi M‑565 apparatus at a ramp rate of 1 °C·min⁻¹ from 140 °C under nitrogen purge, with glass‑capillary sample packing per USP 〈741〉; the endothermic event is sharp, indicating a crystalline form free of amorphous contamination, though polymorphic screening has not been conducted at production scale.
| Parameter | Method | Specification | Result |
|---|---|---|---|
| Appearance | Visual, under D65 illumination | White to off‑white powder | White powder |
| Assay (HPLC, dry basis) | Internal SOP QC‑HPLC‑012, ICH Q2(R1) validated | ≥ 97.0% area | 97.8% |
| Melting range | USP 〈741〉, capillary | 163–168 °C | 164.2–165.8 °C |
| Loss on drying (vacuum, 60 °C, 4 h) | USP 〈731〉 | ≤ 0.5% | 0.22% |
| Water content (KF) | USP 〈921〉, Method Ic | ≤ 1.0% | 0.36% |
| Residue on ignition | USP 〈281〉 | ≤ 0.1% | 0.04% |
| Heavy metals (as Pb) | ICP‑MS, Agilent 7800, ERM‑CD281 reference | ≤ 10 ppm | 3 ppm |
| Residual pyrrolidine | GC‑HS‑FID, DB‑624 30 m × 0.32 mm, USP 〈467〉 | ≤ 0.1% | 0.03% |
| Solubility in DMSO | UV spectrometry at 310 nm | ≥ 50 mg·mL⁻¹ | >60 mg·mL⁻¹ |
Hydrolytic susceptibility of the sulfonamide bridge dictates pre‑drying requirements and storage conditions. Accelerated stability testing at 40 °C / 75% RH (open dish, ICH Q1A conditions) over 4 weeks showed an increase in the des‑sulfonamide degradation product (2‑(4‑aminophenyl)benzothiazole) from 0.4% to 3.1% as quantified by HPLC at 254 nm, while samples stored at 25 °C / 60% RH in a sealed container with activated molecular sieves (4 Å) exhibited no detectable degradation. Therefore, the compound is packaged under argon in septum‑sealed borosilicate vials and must be kept desiccated after opening. Once removed from cold storage, the container should equilibrate to ambient temperature before unsealing to avoid moisture condensation; at relative humidity exceeding 60%, the powder should be handled inside a glove box or under a stream of dry nitrogen.
The synthetic route adopted for scale‑up begins with 2‑(4‑bromophenyl)‑1,3‑benzothiazole, prepared via HCl‑catalysed condensation of 4‑bromobenzaldehyde and 2‑aminothiophenol in ethanol (yield 91% at 200‑g input). Lithium‑halogen exchange is performed in anhydrous THF at −78 °C using n‑BuLi (2.5 M in hexanes, 1.05 eq), held for 45 min before sulfur dioxide gas is introduced at a rate sufficient to maintain a reactor pressure of 0.2 bar above ambient while the jacket is brought to −20 °C. The resulting lithium sulfinate is converted in situ to the sulfonyl chloride by addition of N‑chlorosuccinimide (1.1 eq) in THF at 0 °C, followed by dropwise addition of a THF solution of pyrrolidine (2.2 eq) and triethylamine (2.5 eq) over 30 min while maintaining the internal temperature between 0 °C and 5 °C. The quenched mixture is warmed to 20 °C, washed with 5% aqueous NaHCO₃ and water, dried over MgSO₄, and concentrated to a thick slurry that yields a pale‑yellow solid after trituration with cold ethanol. Recrystallisation from ethanol/water (4:1 v/v) with activated charcoal treatment furnishes the product as a white crystalline powder.
Over 15 consecutively manufactured lots at the 500 g input scale (jacketed glass reactor, anchor stirrer 200 rpm, Julabo FP50 thermostat), the isolated yield after drying to constant weight ranged from 74% to 81%, with an average of 77% and a standard deviation of 2.3%. HPLC purity of the dried product fell consistently within 97.2–98.4% area, and the single‑impurity limit of 0.5% (for the bis‑sulfonamide derived from dimerisation of the sulfinate intermediate) was monitored by LC‑MS with a limit of detection of 0.05%. Residual pyrrolidine, measured by headspace GC on a DB‑624 column as indicated in Table 2, remained below 0.06% in all batches, confirming effective removal during the aqueous work‑up. The crystalline product showed a monomodal particle size distribution (Malvern Mastersizer 3000, dry dispersion) with Dv50 between 28 µm and 42 µm; when required for solubilisation‑limited bioassays, the material can be micronised in an air‑jet mill (Alpine 50 AS) to a Dv90 of ≤ 10 µm without detectable amorphisation as verified by XRPD (Bruker D8 Advance).
Differences from the morpholine and piperidine analogues become pronounced at production scale. The morpholine sulfonamide often co‑crystallises with 0.5–1.0 equivalents of water, requiring prolonged drying at 50 °C under high vacuum and producing a hygroscopic cake that cakes readily in filter dryers. The currently described pyrrolidine sulfonamide remains free‑flowing even after 48 h exposure to 40% RH, thereby streamlining vacuum drying and packaging operations. The piperidine derivative, while also anhydrous, displays a tendency to form N‑nitrosamine impurities when processed in the presence of nitrite‑contaminated wash water; in contrast, the pyrrolidine ring, owing to its reduced basicity (pKa of conjugate acid ≈ 10.3 vs 10.7 for piperidine), shows substantially slower nitrosation kinetics at pH 5–6, a crucial advantage in light of recent EMA and FDA guidance on nitrosamine control.
Published data for this specific configuration is limited, but comparative profiling in internal kinase panels has revealed a characteristic affinity shift. In a radiometric filter‑binding assay (Reaction Biology Corp., ATP concentration at Km), the pyrrolidine sulfonamide exhibited an IC50 of 0.18 µM against CDK2/cyclin E, whereas the morpholine sulfonamide gave 0.95 µM and the piperidine sulfonamide 0.41 µM. Conversely, the morpholine derivative retained strong binding to VEGFR2 (IC₅₀ = 0.26 µM), where the pyrrolidine compound was essentially inactive at 10 µM. Docking studies (Schrödinger Glide, PDB 1H1S for CDK2, 4AG8 for VEGFR2) suggest that the pyrrolidine ring’s preference for an envelope pucker directs the sulfonamide oxygen lone pairs toward the backbone NH of Leu83 in CDK2, a contact that the chair‑like morpholine ring cannot replicate. This geometric difference constitutes a distinct advantage when selectivity over angiogenic kinases is required, and a limitation when broad‑spectrum inhibition is desired.
The pyrrolidine sulfonamide has also attracted attention as a synthetic intermediate for targeted covalent inhibitors. The benzothiazole C‑2 position, once demethylated or halogenated, can serve as a handle for further elaboration with acrylamide warheads. A prototype compound carrying an α‑chloroacetamide at the benzothiazole 6‑position showed selective covalent modification of Cys199 in BTK (HEK293 cell lysate, LC‑MS/MS peptide mapping) with a kinact/KI value of 1.7 × 10⁴ M⁻¹·s⁻¹, while the analogous morpholine‑sulfonamide intermediate led to non‑specific thiol reactivity in serum‑containing medium. The chemotype’s utility is therefore tightly coupled to its nitrogen heterocycle identity; switching to a six‑membered ring changes not only ADMET properties but also the selectivity and reactivity profile of the final drug candidate.
The compound is classified as a skin sensitiser (local lymph node assay, EC3 estimated at 8% w/v in DMF, though data for the neat solid are extrapolated) and a mild eye irritant (BCOP assay, opacity score 12 after 30‑min exposure). Inhalation of fine particulates should be avoided because of the potential for arylamine release during metabolism of the benzothiazole ring; a NIOSH‑approved P100 respirator is advised when handling dry powder outside a fume hood. Operations generating aerosol — sieving, micronising, charging reactors — must be performed under local exhaust ventilation with a face velocity of 0.5 m·s⁻¹ as verified by an anemometer. Nitrile gloves (minimum 0.11 mm thickness, tested to EN 374‑1 for permeation breakthrough time > 480 min) and tightly‑fitting safety goggles (EN 166) constitute the minimum personal protective equipment.
For storage, the product is filled into amber borosilicate vials (Type I, USP 〈660〉) under a nitrogen atmosphere and sealed with PTFE‑lined caps. Long‑term stability data at ‑20 °C over 24 months show no crystallinity change or purity drop within analytical uncertainty; storage at 2–8 °C is permitted for 6 months provided the container remains unopened. Incompatibilities include strong oxidising agents (hydrogen peroxide, peracids), which oxidise the thioether sulfur of the benzothiazole to the corresponding sulfoxide (observed as a +16 Da shift in LC‑MS), and primary or secondary amines under alkaline aqueous conditions, which cleave the sulfonamide bond exothermically. Disposal must comply with local regulations for halogenated organic waste; the compound elutes at 6.8 min under the HPLC conditions given, and environmental release can be monitored by LC‑MS/MS with a detection limit of 0.1 ng·L⁻¹. REACH registration has not been completed for this substance; supply is limited to quantities below 1 tonne per annum under the exemption for scientific research and development (Title II, Chapter 1, Art. 9).
The pyrrolidine‑sulfonyl phenyl benzothiazole thus occupies a specific niche relative to its heterocyclic analogues: lower aqueous solubility but superior crystallinity and drier processing behaviour, a kinase selectivity profile biased away from vascular endothelial growth factor receptors, and a greater tolerance of moisture in bulk storage. These differences must be evaluated against the concrete demands of each discovery programme — there is no universally superior substituent, only a trade‑off between ease of synthesis, stability, and the biological fingerprint required by the target product profile.
